The infectious disease diagnostics market reached $45.91

NEWARK, New Castle, USA, Jan. 23, 2023 (Globe Newswire) — According to the report published by Global Growth Plus Reports Infectious disease diagnostics market It was estimated at $35.50 billion in 2021 It is expected to exceed the rating $45.91 billion by 2030advance in Compound annual growth rate of 2.9% From 2022 to 2030. The report provides detailed analysis of top strategies, drivers, winning opportunities, competitive scenario, fluctuating market trends, market size, statistics, estimations, and key investment pockets. Due to the increasing prevalence of infectious diseases and the increasing demand for early diagnosis of infectious diseases.

Get a sample research report: https://www.growthplusreports.com/inquiry/request-sample/global-infectious-disease-diagnostics-market/8082

Market drivers

The primary driver driving the global infectious disease diagnostics market is the increasing prevalence of infectious diseases such as hepatitis, HIV, and influenza. The demand for diagnostic tests for infectious diseases is increasing as people become more aware of the need for early diagnosis and management of infectious diseases. The high number of elderly people who are more susceptible to infectious diseases due to the deterioration of immunity. Because of the continuous testing required for this suite to prevent major infections, the market for infectious disease diagnostics is growing. The expansion of the Infectious Disease Diagnostics market is greatly influenced by the increase in funding from governmental and non-governmental organizations for laboratory diagnostics and the growing need for point-of-care diagnostic tests. In addition, the market for infectious disease diagnostics is growing as a result of expanding research and development in the field of infectious diseases and the adoption of more advanced technology in disease diagnosis.

The global infectious disease diagnostics market has been analyzed from five aspects – product, technology, disease type, end user, and region

excerpts from “according to the technological division”

On the basis of technology, the global infectious disease diagnostics market is segmented into:

• Polymerase chain reaction (PCR)
• Immunodiagnostics
• Clinical Microbiology
• Next generation sequencing (NGS)
• Isothermal DNA Amplification Technology (INAAT)
• others

In terms of market share, the infectious disease diagnostics market was dominated by the PCR segment in 2021. The growth of this segment is accelerating by using PCR to diagnose some diseases that are difficult to grow in a laboratory or that take a long time to grow. PCR data is obtained much more rapidly than through culture, providing decision-makers with knowledge earlier than they would otherwise. The demand for PCR in the diagnosis of infectious diseases is increasing as a result of the rapid identification of bacteremia that PCR provides, especially for samples with low amounts of bacteria. For the majority of diagnostic tests, such as those for tuberculosis, that are still smear- and culture-based, PCR is still considered as an adjuvant test.

Excerpts from “by Classification of disease type

On the basis of disease type, the global infectious disease diagnostics market is segmented into:

• Lever Inflammation
• human papillomavirus (HPV)
• Hospital acquired infection
• tuberculosis (tuberculosis)
• human immunodeficiency virus (HIV)
• flu
• Diseases transmitted by mosquitoes
• others

In terms of infectious disease diagnostics market share in 2021, the hepatitis category was dominated by disease type. The primary driver of this sectoral growth is the increasing prevalence of hepatitis types B and C. According to the World Health Organization, about 1,100,000 deaths occur due to types B and C. In addition, this sector is growing as a result of expanding research and development in the diagnosis and treatment of hepatitis C as well as an increase in the number of hepatitis doses given to newborns. According to the World Health Organization, globally, approximately 42% of children receive the birth dose of hepatitis B vaccine.

Browse the full report with detailed table of contents at: https://www.growthplusreports.com/report/global-infectious-disease-diagnostics-market/8082

Excerpts from “Classification by Region”

On the basis of region, the global Infectious Disease Diagnostics market has been segmented as:

• North Amarica
• Europe
• Asia Pacific
• the rest of the world

North America dominated the global infectious disease diagnostics market in 2021, followed by Europe. The Asia Pacific market is expected to grow at the fastest CAGR during the forecast period. Growth in the region is greatly boosted by the increasing prevalence of infectious diseases. According to the Centers for Disease Control and Prevention (CDC), about 7,882 people in the United States were affected by tuberculosis (TB) in 2021 and up to 13 million people are living with TB. Regional growth is supported by rising healthcare expenditures and well-developed healthcare infrastructure. Moreover, the growth in the region is exacerbated by an increase in the number of visits to doctors’ offices for infectious and parasitic diseases, as well as an increase in the demand for early detection of infectious diseases. According to the Centers for Disease Control and Prevention (CDC), about 7.2 million people visit doctors’ offices in the US. Moreover, the presence of major players in the region is expected to drive regional growth.

Excerpt from “The Competitive Landscape”

Some of the prominent players operating in the global Infectious Disease Diagnostics Market are:

• Abbott Laboratories
• F. Hoffmann-La Roche Ltd
• Picton, Dickinson and Company
• bioMerieux SA
• Danaher Corporation
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Hologic, Inc.
• Siemens Healthineers AG
• Illumina, Inc.
• Qiagen Company
• Luminex Corporation
• Grifols SA
• Sysmex Corporation

Value propositions related to the report:

• Backed by free analyst hours and expert interviews with every report
• Comprehensive quantitative and qualitative insights at the sector and sub-segment level
• COVID-19 impact trends and perspectives
• Accurate insights at the global/regional/country level
• Deep-rooted insights into market dynamics (drivers, constraints, opportunities) and business environment
• Comprehensive coverage of the competitive landscape
• Winning imperatives
• Comprehensive coverage on “strategic developments” recorded by the leading market players

Customization options:

• Distributor Landscape Assessment
• pricing intelligence
• Evaluate the customer base
• Analysis of initiatives and investment
• “Business Profile” of the main players

Inquire before buying: https://www.growthplusreports.com/inquiry/before-buying/global-infectious-disease-diagnostics-market/8082

about us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge services company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

The Growth Plus suite of services builds on our core capabilities of secondary and primary research, market modeling and forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, groundbreaking solutions that prepare them for future growth and success.

We have been awarded by the prestigious CEO Magazine as the “Most Innovative Healthcare Market Research Firm in 2020.”